(News Bulletin 247) – Jefferies initiates, this Monday, hedging of the Merck share for the purchase with a price target of $125.
‘Merck presents a better growth profile in terms of EPS than its large-cap peers’, begins the analyst for whom the flagship drug, Keytruda, is ‘poorly evaluated by investors’.
Add the figures of Sotatercept, ‘on the rise’ and the cardiovascular segment, ‘with maximum sales estimated at 10 billion dollars’.
Above all, Gardasil has ‘great growth opportunity in China and stable growth levels in the United States’, notes Jefferies. And to see that HPV vaccine reach $11 billion by 2030 ‘and continue to grow beyond that’.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
